The MutHER trial (https://www.clinicaltrials.gov, NCT01670877), a Phase II study investigating neratinib alone and in combination with fulvestrant in metastatic HER2 non-amplified, HER2 mutant BC was launched in 2012. Here, ERBB2 is linked to breast cancer.